Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08) Meeting Abstract


Authors: Jhaveri, K.; Hamilton, E.; Loi, S.; Schmid, P.; Darilay, A.; Gao, C.; Patel, G.; Wrona, M.; Andre, F.
Abstract Title: Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
Meeting Title: 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS)
Journal Title: Cancer Research
Volume: 81
Issue: 4 Suppl.
Meeting Dates: 2020 Dec 8-11
Meeting Location: San Antonio, TX
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2021-02-01
Language: English
ACCESSION: WOS:000618737700039
PROVIDER: wos
DOI: 10.1158/1538-7445.SABCS20-OT-03-05
Notes: Meeting Abstract: OT-03-05 -- This symposium was held virtually due to COVID-19 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Komal Lachhman Jhaveri
    201 Jhaveri